Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | CCR3 | P51677 | 1/20 | 0.61 |
| ▸ | GRM5 | P41594 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363800 | 1.00 | ALDH1A1 (0.72) | ALDH1A1TSHRMCHR1LMNASMN1; SMN2 | |
| SCHEMBL2468483 | 0.89 | NPC1 (0.71) | ALDH1A1TSHRMCHR1LMNASMN1; SMN2 | |
| SCHEMBL3702296 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRMCHR1LMNASMN1; SMN2 | |
| SCHEMBL16222341 | 0.87 | ALDH1A1 (0.56) | ALDH1A1TSHRMCHR1LMNASMN1; SMN2 | |
| SCHEMBL1667825 | 0.86 | RAB9A (0.73) | ALDH1A1TSHRLMNASMN1; SMN2GRM5 | |
| SCHEMBL14980323 | 0.85 | ROCK2 (0.56) | ALDH1A1TSHRMCHR1LMNASMN1; SMN2 | |
| SCHEMBL10212211 | 0.85 | ALDH1A1 (0.64) | ALDH1A1TSHRMCHR1LMNASMN1; SMN2 | |
| SCHEMBL11241115 | 0.85 | RAB9A (0.75) | ALDH1A1TSHRLMNASMN1; SMN2GRM5 | |
| SCHEMBL30564259 | 0.84 | ALDH1A1 (0.56) | ALDH1A1TSHRMCHR1LMNASMN1; SMN2 | |
| SCHEMBL29530983 | 0.84 | ALDH1A1 (0.72) | ALDH1A1TSHRMCHR1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | PMV PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| CN-119490507-A | Novel kinase inhibitor | 首药控股(北京)股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-11938124-B2 | Combination therapy for treatment of cancer | PMV PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| WO-2023160614-A1 | COMPOUND AS FAK INHIBITOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 | 2023-08-31 | — | — | WO | disclosed |
| WO-2023036252-A1 | PYRROLOPYRIMIDINE OR PYRROLOPYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | 希格生科（深圳）有限公司 | 2023-03-16 | — | — | WO | disclosed |
| US-20230049952-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230044826-A1 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | PMV PHARMACEUTICALS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20230033324-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20230024905-A1 | USES OF P53 X-RAY CO-CRYSTAL STRUCTURES | PMV PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-3828185-A2 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-2205603-B1 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2014-01-15 | — | — | EP | disclosed |
| WO-2009065570-A1 | NON-PEPTIDIC PROMOTERS OF APOPTOSIS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2009-05-28 | — | — | WO | disclosed |
| EP-2029599-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | Astra Zeneca AB (SE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007135374-A1 | DIHYDROPTERIDINE COMPOUNDS AS ANTI PROLIFERATIVE AGENTS | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11938124-B2 | Combination therapy for treatment of cancer | TP53, KRAS, TP53BP1 | ALDH1A1 2000/4885TSHR 3698/4885MCHR1 4664/4885 |
| US-20230049952-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | ALDH1A1 1538/4885TSHR 3846/4885MCHR1 4783/4885 |
| US-20230033324-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | ALDH1A1 2000/4885TSHR 3698/4885MCHR1 4664/4885 |
| US-20230044826-A1 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | TP53, TP53BP1, KRAS | ALDH1A1 1835/4885TSHR 3665/4885MCHR1 4857/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | ALDH1A1 1944/4885TSHR 2806/4885MCHR1 4548/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | ALDH1A1 3910/4885TSHR 1092/4885MCHR1 4053/4885 |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | ALDH1A1 2000/4885TSHR 3698/4885MCHR1 4664/4885 |
| US-20230024905-A1 | USES OF P53 X-RAY CO-CRYSTAL STRUCTURES | TP53, TP53BP1, MDM2 | ALDH1A1 3539/4885TSHR 2705/4885MCHR1 4722/4885 |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | TP53, TP53BP1, KRAS | ALDH1A1 1835/4885TSHR 3665/4885MCHR1 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.